Genetic variants involved in blood pressure response to losartan identified by GWAS methodology

TL;DRAbstract

<b>Aim:</b> to identify genetic variants involved in blood pressure response to Losartan, an angiotensin II receptor blocker, with a whole genome approach.
\n<br><b>Methods:</b> n=722 never treated patients from Italy (SOPHIA study) with Essential Hypertension (EH): Losartan 50 mg o.d. was prescribed for 4 weeks to 539 patients. A genome-wide association study and imputation were perfomed on 494 patients. After quality control 372 patients remained for analysis To confirm the specificity of our findings, we tested their association with deltaSBP at 4wks in 458 patients treated with HCTZ. The best markers were tested for replication in two independent cohorts of hypertensives from the GERA2 and GENRES studies. </br>
\n<b>Results:</b> 131 SNPs were associated with deltaSBP4 (P≤10<sup>-5</sup>), 121 of them to diastolic BP response. A peak of association in the Calcium/Calmodulin-dependent protein Kinase I D gene (CAMK1

Chat with Paper

AI Agents for this Paper